219 Article(s)
Pub. Date
#Total Relationship(s)
1 9056009 Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 1997 Mar 2
2 9211082 Nelfinavir. Drugs 1997 Jul 1
3 9617598 Amprenavir. Drugs 1998 Jun 1
4 9649346 Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions. J Pharm Sci 1998 Jul 1
5 9660842 Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. Drug Metab Dispos 1998 Jul 11
6 9803961 Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. J Acquir Immune Defic Syndr Hum Retrovirol 1998 Nov 1 2
7 9835508 Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. Antimicrob Agents Chemother 1998 Dec 2
8 9878993 Efavirenz. Drugs 1998 Dec 1
9 10049256 Inhibition of human immunodeficiency virus type 1 replication by combination of transcription inhibitor K-12 and other antiretroviral agents in acutely and chronically infected cells. Antimicrob Agents Chemother 1999 Mar 1
10 10066640 Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy. Eur J Med Res 1999 Feb 25 1
11 10381636 Dynamic correlation of apoptosis and immune activation during treatment of HIV infection. Cell Death Differ 1999 May 1
12 10452644 Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate. Clin Infect Dis 1999 May 1
13 10509562 Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS 1999 Sep 10 4
14 10597780 Beneficial effects of protease inhibitors on body composition and energy expenditure: a comparison between HIV-infected and AIDS patients. AIDS 1999 Dec 3 1
15 10651392 Didanosine: an updated review of its use in HIV infection. Drugs 1999 Dec 1
16 10776836 Nelfinavir: an update on its use in HIV infection. Drugs 2000 Mar 1
17 10820137 Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 2000 Jun 1
18 10926350 Drug interactions with cisapride: clinical implications. Clin Pharmacokinet 2000 Jul 1
19 10939550 Variability in activity of hepatic CYP3A4 in patients infected with HIV. Pharmacotherapy 2000 Aug 1
20 10954886 Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial--PACTG 377. Pediatric AIDS Clinical Trials Group 377 Study Team. AIDS Res Hum Retroviruses 2000 Aug 10 2
21 10996400 HIV protease inhibitors block adipogenesis and increase lipolysis in vitro. Antiviral Res 2000 Aug 2
22 11116063 HIV protease inhibitors stimulate hepatic triglyceride synthesis. Arterioscler Thromb Vasc Biol 2000 Dec 1
23 11120614 Highly active antiretroviral therapy normalizes the potential for MIP-1alpha production in HIV infection. J Infect 2000 Nov 1
24 11159797 Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. Drug Metab Dispos 2001 Feb 2
25 11185676 A study of the pharmacokinetics of azithromycin and nelfinavir when coadministered in healthy volunteers. J Clin Pharmacol 2000 Dec 1
26 11302944 Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metab Dispos 2001 May 2
27 11375344 The HIV protease inhibitor nelfinavir induces insulin resistance and increases basal lipolysis in 3T3-L1 adipocytes. Diabetes 2001 Jun 3
28 11399981 Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients. AIDS 2001 May 25 1
29 11468419 HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART. J Acquir Immune Defic Syndr 2001 Aug 1 1
30 11477322 Nelfinavir plasma levels under twice-daily and three-times-daily regimens: high interpatient and low intrapatient variability. Ther Drug Monit 2001 Aug 1
31 11590524 Comparative CD4 T-cell responses of reverse transcriptase inhibitor therapy with or without nelfinavir matched for viral exposure. HIV Clin Trials 2001 Mar-Apr 2
32 12176683 Effect of antiretroviral triple combinations including the protease inhibitor nelfinavir in heavily pretreated children with HIV-1 infection. Eur J Med Res 2002 Jul 24 1
33 12189360 Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir. Clin Pharmacol Ther 2002 Aug 1
34 12403023 A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients. West Afr J Med 2002 Apr-Jun 1
35 12405866 Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin Pharmacokinet 2002 1
36 12435624 Limited effect of food composition on the pharmacokinetics of nelfinavir administered twice daily. Eur J Med Res 2002 Oct 29 1
37 12477837 Isolation and molecular characterization of a nelfinavir (NFV)-resistant human immunodeficiency virus type 1 that exhibits NFV-dependent enhancement of replication. J Virol 2003 Jan 1
38 12478066 Agent and cell-type specificity in the induction of insulin resistance by HIV protease inhibitors. AIDS 2003 Jan 3 5
39 12545146 Effects of nelfinavir and its M8 metabolite on lymphocyte P-glycoprotein activity during antiretroviral therapy. Clin Pharmacol Ther 2003 Jan 8
40 12689411 Greater reversal of CD4+ cell abnormalities and viral load reduction after initiation of antiretroviral therapy with zidovudine, lamivudine, and nelfinavir before complete HIV type 1 seroconversion. AIDS Res Hum Retroviruses 2003 Mar 1
41 12705974 Sensitive and specific determination of eight antiretroviral agents in plasma by high-performance liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2003 May 25 1
42 12837856 Modulation of the LDL receptor and LRP levels by HIV protease inhibitors. J Lipid Res 2003 Oct 9
43 12902797 The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro. J Acquir Immune Defic Syndr 2003 Aug 15 4
44 12917239 Effect of protease inhibitor-containing regimens on lymphocyte multidrug resistance transporter expression. J Antimicrob Chemother 2003 Sep 2
45 12949316 Nelfinavir pharmacokinetics in stable human immunodeficiency virus-positive children: Pediatric AIDS Clinical Trials Group Protocol 377. Pediatrics 2003 Sep 1
46 12949438 Inhibition of cytochrome P450 3A: relevant drug interactions in gastroenterology. Digestion 2003 1
47 14592951 Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice. Endocrinology 2004 Feb 1
48 15002082 A randomized clinical trial comparing nelfinavir and ritonavir in patients with advanced HIV disease (CPCRA 042/CTN 102). HIV Clin Trials 2004 Jan-Feb 2
49 15007102 HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther 2004 Jul 1
50 15040543 Intracellular accumulation of nelfinavir and its relationship to P-glycoprotein expression and function in HIV-infected patients. Antivir Ther 2004 Feb 6